ImmunoPrecise Antibodies Competitors

Pharvaris B.V. (NASDAQ:PHVS) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Pharvaris B.V. and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharvaris B.V. and ImmunoPrecise Antibodies, as provided by MarketBeat.

Pharvaris B.V. currently has a consensus target price of $47.50, indicating a potential upside of 63.76%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris B.V. is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares Pharvaris B.V. and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Summary

Pharvaris B.V. beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares 4D Molecular Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for 4D Molecular Therapeutics and ImmunoPrecise Antibodies, as provided by MarketBeat.

4D Molecular Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 32.19%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares 4D Molecular Therapeutics and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Summary

4D Molecular Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Gracell Biotechnologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gracell Biotechnologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

Gracell Biotechnologies currently has a consensus target price of $34.50, indicating a potential upside of 148.38%. Given Gracell Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares Gracell Biotechnologies and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Summary

Gracell Biotechnologies beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and iTeos Therapeutics, as provided by MarketBeat.

iTeos Therapeutics has a consensus target price of $49.40, indicating a potential upside of 103.54%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than ImmunoPrecise Antibodies.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and iTeos Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares ImmunoPrecise Antibodies and iTeos Therapeutics' net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

iTeos Therapeutics beats ImmunoPrecise Antibodies on 4 of the 4 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Pharming Group, as provided by MarketBeat.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Pharming Group's top-line revenue, earnings per share and valuation.

Profitability

This table compares ImmunoPrecise Antibodies and Pharming Group's net margins, return on equity and return on assets.

ImmunoPrecise Antibodies (NASDAQ:IPA) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Finch Therapeutics Group, as provided by MarketBeat.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Finch Therapeutics Group's top-line revenue, earnings per share and valuation.

Profitability

This table compares ImmunoPrecise Antibodies and Finch Therapeutics Group's net margins, return on equity and return on assets.